RESUMO
The characteristics of aerogel materials such as the low density and large surface area enable them to adsorb large amounts of substances, so they show great potential for application in industrial wastewater treatment. Herein, using a combination of completely environmentally friendly materials such as cellulose nanofibers (CNFs) extracted from the petioles of the nipa palm tree and graphene oxide (GO) fabricated by simple solvent evaporation, a composite aerogel was prepared by a freeze-drying method. The obtained aerogel possessed a light density of 0.0264 g/cm3 and a porosity of more than 98.2%. It was able to withstand a weight as much as 2500 times with the maximum force (1479.5 N) to break up 0.2 g of an aerogel by compression strength testing and was stable in the aquatic environment, enabling it to be reused five times with an adsorption capacity over 90%. The CNF/GO aerogel can recover higher than 85% after 30 consecutive compression recovery cycles, which is convenient for the reusability of this material in wastewater treatments. The obtained aerogel also showed a good interaction between the component phases, a high thermal stability, a 3D network structure combined with thin walls and pores with a large specific surface area. In addition, the aerogel also exhibited a fast adsorption rate for methylene blue (MB) adsorption, a type of waste from the textile industry that pollutes water sources, and it can adsorb more than 99% MB in water in less than 20 min. The excellent adsorption of MB onto the CNF/GO aerogel was driven by electrostatic interactions, which agreed with the pseudo-second-order kinetic model with a correlation coefficient R 2 = 0.9978. The initial results show that the CNF/GO aerogel is a highly durable "green" light material that might be applied in the treatment of domestic organic waste water and is completely recoverable and reusable.
RESUMO
Human bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) represent promising stem cell therapy for the treatment of type 2 diabetes mellitus (T2DM), but the results of autologous BM-MSC administration in T2DM patients are contradictory. The purpose of this study was to test the hypothesis that autologous BM-MSC administration in T2DM patient is safe and that the efficacy of the treatment is dependant on the quality of the autologous BM-MSC population and administration routes. T2DM patients were enrolled, randomly assigned (1:1) by a computer-based system into the intravenous and dorsal pancreatic arterial groups. The safety was assessed in all the treated patients, and the efficacy was evaluated based on the absolute changes in the hemoglobin A1c, fasting blood glucose, and C-peptide levels throughout the 12-month follow-up. Our data indicated that autologous BM-MSC administration was well tolerated in 30 T2DM patients. Short-term therapeutic effects were observed in patients with T2DM duration of <10 years and a body mass index <23, which is in line with the phenotypic analysis of the autologous BM-MSC population. T2DM duration directly altered the proliferation rate of BM-MSCs, abrogated the glycolysis and mitochondria respiration of BM-MSCs, and induced the accumulation of mitochondria DNA mutation. Our data suggest that autologous administration of BM-MSCs in the treatment of T2DM should be performed in patients with T2DM duration <10 years and no obesity. Prior to further confirming the effects of T2DM on BM-MSC biology, future work with a larger cohort focusing on patients with different T2DM history is needed to understand the mechanism underlying our observation.
